智飞生物重组带状疱疹ZFA01佐剂疫苗（CHO细胞）临床试验申请获得受理

Core Viewpoint - The announcement by Zhifei Biological (300122) regarding the acceptance of the clinical trial application for its recombinant herpes zoster vaccine ZFA01 by the National Medical Products Administration signifies a significant advancement in the company's vaccine development efforts [1] Group 1: Clinical Trial Approval - Zhifei Biological's subsidiary, Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial application of the ZFA01 adjuvanted vaccine [1] - The company can commence clinical trials within 60 days if no negative or questioning opinions are received from the drug review center [1] Group 2: Vaccine Technology and Innovation - The ZFA01 vaccine utilizes a newly developed adjuvant that can stimulate both cellular and humoral immune responses, potentially enhancing the vaccine's protective efficacy [1] - The acceptance of the clinical trial application reflects the successful application of the company's innovative adjuvant technology platform, focusing on innovation and strengthening core competencies [1] Group 3: Market Position and Product Portfolio - Successful progress of this project is expected to enrich the company's adult vaccine offerings, improve its product layout, and strengthen its market position [1]